NEW YORK, Jan. 21 - Genaissance Pharmaceuticals and Bayer Diagnostics said today they are collaborating on finding pharmacogenomics markers for drug safety and efficacy.
In the partnership, Genaissance will use its HAP technology to analyze clinical samples provided by the diagnostics division of Bayer HealthCare.
Terms of the deal call for Genaissance to receive royalties and rights to perform diagnostic tests developed and marketed by Bayer, according to the companies.
Financial details of the agreement were not disclosed.
Click here for more information.